If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
119
results.
Updated on
01/04/2026 [07:57:00]
Absstract of: CN121698795A
本公开提供了一种脂质化合物和脂质纳米颗粒组合物，所述脂质化合物具有如式I所示结构。本公开提供的脂质纳米颗粒粒径分布较好，包封率高，且递送效果优异，能够满足体内递送的需求。
Absstract of: CN121695073A
本发明涉及一种负载中药活性外泌体的可注射温敏水凝胶，属于糖尿病足难愈性创面的临床治疗技术领域，可注射温敏水凝胶由泊洛沙姆407水凝胶和透明质酸负载复合载体质得到；所述复合载体质由包衣液包覆中药活性外泌体形成；中药活性外泌体由脂肪间充质干细胞经改性黄芪提取物诱导后得到。通过可注射温敏水凝胶由泊洛沙姆407水凝胶和透明质酸负载复合载体质得到，泊洛沙姆407和透明质酸在注射后迅速于创面形成物理屏障，提供湿润愈合环境，并依托其温敏特性和网络结构，实现外泌体与活性成分的持续缓慢释放，避免药物突释导致的局部浓度过高或过早流失。
Absstract of: CN121695105A
本发明公开了一种基于高频振荡剪切微流控技术的核酸共包封方法及应用，通过调控微流控剪切力与频率，将不同的核酸药物分子分层包封于脂质体纳米颗粒的特定区域（外围或核心），实现可控的时序释放与表达，从根本上解决不同核酸精准包封与释放时序控制的难题，以提升核酸药物的疗效与安全性，适用于制备肿瘤疫苗、传染病预防、基因治疗等相关产品中的领域。
Absstract of: CN121698390A
本申请属于仿生纳米材料技术领域，具体公开了一种含钆锰基钙钛矿型纳米酶及其制备方法和应用。所述的含钆锰基钙钛矿型纳米酶通过溶胶‑凝胶法合成，然后经细胞膜包覆后形成具有核‑壳结构的细胞膜包被的GMO纳米酶制剂。该GMO纳米酶和细胞膜包被的GMO纳米酶制剂均具有的类乳酸氧化酶活性。特别是细胞膜包被的GMO纳米酶制剂还具有很好的生物安全性，因此细胞膜包被的GMO纳米酶制剂可作为高效的生物催化治疗剂，用于调控肿瘤微环境，在抗肿瘤相关疾病的治疗中具有广阔应用前景。本发明为构建兼具高稳定性与高生物安全性的仿生纳米酶平台提供了一种高效可行的技术策略。
Absstract of: CN121695181A
本发明公开了一种自组装纳米复合材料及其制备方法与应用，属于新型纳米材料制备技术领域。该自组装纳米复合材料包括铜基金属有机框架，包裹在所述铜基金属有机框架内部的外泌体，包覆在所述铜基金属有机框架外部的聚多巴胺，以及修饰在聚多巴胺表面的ASGR1抗体。本发明将纳米酶的催化治疗、外泌体的生物学调控与抗体的分子靶向功能进行巧妙整合，通过多机制协同作用，应对MASLD复杂的病理网络。本发明不仅提供了一种有效的候选治疗材料，还为理解基于外泌体与纳米酶的联合治疗机制提供了多组学视角，具有重要的理论意义与转化应用潜力。
Absstract of: CN121699024A
本发明涉及医药技术领域，尤其涉及人重链铁蛋白或其变体与多角体或颗粒体蛋白的融合蛋白及应用。本发明将铁蛋白变体与杆状病毒多角体蛋白亚基融合，得到由多角体蛋白外层及铁蛋白内层组成的粒径＜20nm的粒子，其外径17nm，内腔13nm且带有正电荷，通过pH调节实现外层和内层的解聚和重组，可包载带负电且＞8nm的胰岛素分子。多角体或颗粒体蛋白的亚基同铁蛋白野生型或突变型融合的蛋白可自组装成双层结构的纳米颗粒，其内层为内腔带正电或负电、大小为8nm或13nm的笼型结构；外层为多角体或颗粒体蛋白层，具有抗逆性，可耐高温、脱水且可抵抗胃蛋白酶和胰蛋白酶的消化。该纳米颗粒可作为多种活性分子的口服载体。
Absstract of: CN121695102A
本发明涉及mRNA疫苗脂质纳米粒制备技术领域，具体公开一种全流程低温快速混合制备方法。该方法包括：将可电离脂质、辅助脂质、胆固醇和PEG脂质溶解于含防冻剂的无水乙醇中并在0-10°C预冷；将mRNA溶于低离子强度酸性缓冲液，加入低温保护剂形成均一水相；在0-10°C下通过亲水改性的微流控芯片按(2.5-3.5):1流速比混合，满足雷诺数≥2000和韦伯数≥100，在10 ms内完成混合，随后低温熟化、两步缓冲液置换及低温切向流过滤，获得粒径70-90 nm、PDI≤0.15、包封率≥95%的LNP。防冻剂和保护剂协同作用有效抑制乙醇结晶和冰晶损伤，保证低温条件下微通道不堵塞，显著提高粒径均一性和mRNA结构完整性，所得制剂在4°C和-20°C下长期稳定。
Absstract of: CN121695106A
本发明提供了一种M2巨噬细胞外泌体负载卡格列净纳米药物及其应用，以M2巨噬细胞外泌体为载体，卡格列净负载在M2巨噬细胞外泌体上。本发明首次构建了Exo‑CANA递送体系，外泌体体积小，可有效避免单核巨噬细胞的吞噬作用，可自由穿过血管壁和细胞外基质，能显著改善Th2型气道炎症、杯状细胞化生及肺间质胶原沉积，且治疗效果显著优于CANA单药治疗组、M2‑Exos单药治疗组。
Absstract of: CN121695058A
本发明涉及化妆品及其生物技术领域，具体地涉及一种利用黑兰细胞包裹玉米胚芽提取物的囊泡组合物及其制备方法和应用。本发明所述的囊泡组合物是将玉米胚芽提取物流加至黑兰细胞的发酵体系中获得。所述黑兰细胞的发酵体系的培养条件为温度22‑25℃，120‑180 rpm，培养周期15‑20天。所述的玉米胚芽提取物可以选择在步骤黑兰细胞的发酵培养的延滞期、指数期、指数后期及平台期加入。本发明所得的黑兰细胞囊泡组合物具有低免疫原性、细胞摄取增强、更高的稳定性、靶向能力，与皮肤角质层的磷脂双分子层亲和性更佳。到达皮肤角质层后，可以迅速释放活性物，从而达到作用功效。可以用于制备抗氧化或抗衰老的药品或化妆品。
Absstract of: CN121695103A
本发明属于纳米生物材料技术领域，具体涉及一种基于溶剂平衡与巯基锚定的细胞膜包覆纳米颗粒制备方法。该方法通过在膜体系中掺入含巯基脂质，使其与基底表面形成共价锚定键以增强膜‑基底结合力，并加入少量有机溶剂提高脂质流动性，促进膜层在颗粒表面的自发融合与均匀铺展。经离心与洗涤后即可获得表面包覆完整的细胞膜纳米颗粒。该方法无需高能超声或挤出处理，能在保持膜蛋白与脂质组成完整的前提下实现稳定包覆，显著提升膜层在高盐及剪切环境下的附着稳定性。该方法适用于多种纳米基底及不同形貌结构，所得颗粒在抗α‑溶血素疫苗模型中表现出更高抗体滴度与优异安全性。本发明提供了一种温和、高效且具有广泛适用性的仿生纳米材料构筑策略。
Absstract of: AU2024322931A1
Compositions and methods for delivery of nucleic acid therapeutics are disclosed herein. In some embodiments, a composition for treating a subject includes a dynamic hydrogel, and a nucleic acid therapeutic encapsulated by the dynamic hydrogel. The dynamic hydrogel can include a polymer and a plurality of nanoparticles. The polymer can be non-covalently crosslinked with the plurality of nanoparticles.
Absstract of: AU2024308529A1
Provided are lipid nanoparticles for delivering nucleic acids molecules such as mRNA. Also provided are methods of making and using thereof.
Absstract of: US20260028427A1
The present invention relates to a multispecific antibody comprising at least a FAPα binding region comprising a first heavy chain variable region and a first light chain variable region; and a DR4 binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
Absstract of: CN121699931A
本发明提供一种UTR元件HBB‑G及其构建方法和应用，涉及mRNA技术领域。本发明通过PaddleHelix平台对Homo sapiens haplotype T7 delta‑globin(NCBI编号为AF339412.1)的5'UTR进行核糖体载量预测和二级结构优化，获得的优化序列避免了抑制性发夹结构，使荧光素酶表达量较天然UTR明显提升。在优化序列基础上引入无二级结构的ncRNA序列，进一步解除5'cap区域的翻译抑制，构建的HBB‑G突变体（HBB‑G的DNA序列如SEQ NO.1所示，RNA序列如SEQ NO.2所示）使蛋白表达量进一步提升。
Absstract of: CN121695165A
本发明公开了ITSN1抑制剂及其在制备预防和/或治疗肝纤维化药物中的应用，属于分子生物学及肝病治疗技术领域。根据ITSN1在纤维化肝脏的LSEC中异常高表达，通过敲低ITSN1实验，发现ITSN1作为LSEC分化的负调控因子，其敲低可通过恢复LSEC分化表型及增加孔隙度，有效逆转肝窦毛细血管化进程。通过给予siITSN1抑制剂观察LSEC体外血管形成，发现siITSN1抑制剂能够显著抑制LSEC的血管生成能力以及延缓其动力学进程。通过给予siITSN1抑制剂干预LSEC对HSC活化，发现ITSN1敲低的LSEC通过旁分泌信号显著抑制HSC活化及胶原沉积。因此，ITSN1抑制剂具有用于预防和/或治疗肝纤维化的潜力。
Absstract of: AU2024327040A1
A method for preparing nucleic acid-containing lipid nanoparticles (NALNP) from a nucleic acid-containing neutral pH ionic salt solution and a lipid solution is provided. The method includes combining the nucleic acid-containing neutral pH ionic salt solution and the lipid solution and forming a combined mixture. The method further includes introducing an aqueous solution of lower ionic concentration than that of the neutral pH ionic salt solution into the combined mixture, thereby creating an ionic flux and forming the nucleic acid-containing lipid nanoparticles (NALNP).
Absstract of: WO2026060137A1
Lipid-polymer conjugates and associated lipid nanoparticles are described herein. Such conjugates can comprise polyoxazolines and/or poly oxazines, thereby obviating the use of PEG-based treatments.
Absstract of: WO2026055729A1
The present invention relates to stable nucleic acid LNP vaccine formulations for administration via a microprojection array in which the microprojections are densely packed and in which the vaccine formulations are rapidly sprayed or layered on to the microprojections in relatively small amounts such that the formulations dry rapidly. The present invention relates in particular to stabilized RNA-LNP vaccines delivered by high density micro-array patches (HD-MAPs).
Absstract of: US20260077057A1
Provided is a novel carrier for introducing a nucleic acid such as a siRNA into a cell. The carrier for a nucleic acid of the present invention includes vesicles from a plant in the family Malpighiaceae, and preferably vesicles derived from acerola. A method for administering a nucleic acid according to the present invention includes forming a conjugate of the carrier for a nucleic acid of the present invention and a nucleic acid and administering the conjugate.
Absstract of: US20260077038A1
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
Absstract of: US20260076920A1
According to some embodiments, a carrier for reducing a likelihood of a pathogen binding to cell structures of a host comprises a core, surface features extending from an exterior surface of the core, wherein the surface features are configured to bind to target areas of cell structures of the host to at least partially block the pathogen from binding to said target areas as a result of competitive inhibition, and a plurality of binding sites along the exterior surface, wherein the binding sites are configured to attract at least one portion of the pathogen, wherein the binding sites are recognizable by the pathogen and are able to be bound by the pathogen, thereby at least partially immobilizing the pathogen and reducing the likelihood of the pathogen binding to target areas of cell structures of the host.
Absstract of: US20260076914A1
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
Absstract of: US20260076905A1
The invention includes lipid nanoparticles (LNP) capable of eliciting a modulated immune response against an antigen in a subject. The LNPs comprise: (a) at least one first nucleoside-modified ribonucleic acid (RNA) encoding an antigen; (b) at least one second nucleoside-modified RNA encoding a cytokine or immune receptor (such as but not limited to a cytokine receptor); and (c) at least one ionizable lipid. The invention also includes pharmaceutical compositions comprising the LNP of the invention, as well as a method of eliciting a modulated immune response against an antigen in a subject, the method comprising administering an effective amount of a pharmaceutical compositions comprising the LNP of the invention.
Absstract of: US20260077063A1
The present disclosure provides, for instance, polymer-lipid hybrid nanoparticle compositions and methods of making and using them. The polymer-lipid hybrid nanoparticle may comprise, for example, poly(lactic-co-glycolic) acid (PLGA), polyethylenimine (PEI), and D-Lin-MC3-DMA (MC3). The polymer-lipid hybrid nanoparticle can be used to deliver, for example, nucleic acids and small molecules, cells.
Nº publicación: US20260077059A1 19/03/2026
Applicant:
BATTELLE MEMORIAL INST [US]
BATTELLE MEMORIAL INSTITUTE
Absstract of: US20260077059A1
Compositions and methods are provided for inactivating ghrelin in mammalian cells by administration of a polynucleotide encoding a butyrylcholinesterase (BChE) enzyme.
BOPI
Electronic site
